Morphic Medical

GI Dynamics is Now Morphic Medical. Learn More.

UK 1st National Health Service (NHS) EndoBarrier Service: Outcomes in 1st 38 Patients to Reach 6 Months after Device Explant

Our data demonstrate EndoBarrier as highly effective in patients with refractory diabesity. Maintenance of improvement after EndoBarrier removal was achieved in 68%. There were high patient satisfaction levels and an acceptable safety profile. As endoscopy units are ubiquitous, our service could be readily disseminated. Hepatic Abscess is a known risk as a result of EndoBarrier treatment. Clinicians should be vigilant for this complication but if it occurs the device can, if necessary, be removed. These data are supportive of risk:benefit being strongly towards benefit and they support the continuance of EndoBarrier as an important treatment option for refractory diabesity.


How RESET Works

Maintenance of Efficacy After RESET

BBC News Item

DJBL for the Treatment of Type 2 Diabetes and Obesity: EASD 2022